Status:
RECRUITING
Exploring Eye Vergence Markers ADHD) and ASD
Lead Sponsor:
Elizabeth Kilbey
Collaborating Sponsors:
Braingaze
Conditions:
Attention Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Eligibility:
All Genders
6+ years
Brief Summary
The investigators study aims to evaluate the utility of eye vergence, an eye-tracking measure, as an indicator of visuo-spatial attention in children aged 4-17 years and adults, using computer-based e...
Eligibility Criteria
Inclusion
- Clinical Groups: Patients currently undergoing or who have previously undergone an assessment for either ADHD and/or Autism at either the CAN centre or Dr Kilbey's private practice in Beckenham.
- Control Group: Subjects without a diagnosis of either ADHD nor Autism, who show no traits of these conditions.
- People of any gender/sex who are aged older than 6 years old.
Exclusion
- Those with non-corrected vision - e.g. near-sightedness, far-sightedness, strabismus or nystagmus
- Individuals with any other oculomotor deficiency, blindness or vision loss.
Key Trial Info
Start Date :
February 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06885060
Start Date
February 1 2025
End Date
January 31 2027
Last Update
March 19 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Braingaze SL
Barcelona, Catalonia, Spain, 08302
2
The Dr Kilbey Practice
Beckenham, London, United Kingdom, BR3 5AA
3
Child and Adult Neurodevelopment Assessment Ltd
New Malden, London, United Kingdom, KT3 4BH